{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:30:43Z","timestamp":1793734243172,"version":"4.6.1"},"reference-count":90,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Anti-vascular endothelial growth factor (VEGF) therapy has emerged as an important adjunct in the management of uveitis, particularly for complications driven by vascular permeability and ischemia, such as uveitic macular edema, inflammatory choroidal neovascularization, and retinal neovascularization (RNV). By directly neutralizing VEGF, these agents offer rapid anatomical improvement and visual stabilization, especially in patients who are steroid-intolerant or present with refractory disease. Although current evidence is largely derived from small series and observational data, the accumulating clinical experience highlights a meaningful therapeutic role for anti-VEGF agents when used in conjunction with appropriate immunosuppression or antimicrobial therapy. Emerging roles extend to inflammatory RNV, tubercular granulomas, and serous retinal detachment. However, sterile intraocular inflammation, vasculitis, and rare endophthalmitis remain important safety concerns. Evolving delivery strategies, including sustained-release formulations, posterior sub-Tenon and exploratory topical approaches, may further expand their utility while improving safety. This review synthesizes current evidence, mechanistic insights, and future directions for integrating anti-VEGF therapy in uveitis care.<\/jats:p>","DOI":"10.4103\/ijo.ijo_2975_25","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:01:09Z","timestamp":1777478469000},"page":"698-706","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Anti-vascular endothelial growth factor therapy in uveitis: Bridging inflammation and vascular pathology"],"prefix":"10.4103","volume":"74","author":[{"given":"Ankush","family":"Kawali","sequence":"first","affiliation":[{"name":"Department of Uveitis and Ocular Immunology, Narayana Nethralaya, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Bhakti","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Uveitis and Ocular Immunology, Narayana Nethralaya, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmamalini","family":"Mahendradas","sequence":"additional","affiliation":[{"name":"Department of Uveitis and Ocular Immunology, Narayana Nethralaya, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Shetty","sequence":"additional","affiliation":[{"name":"Department of Uveitis and Ocular Immunology, Narayana Nethralaya, Bengaluru, Karnataka, India"},{"name":"Department of Refractive Surgery, Narayana Nethralaya, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"R1-20261103","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/09273948.2019.1576910","article-title":"Epidemiology of macular edema in uveitis","volume":"27","author":"Accorinti","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"R2-20261103","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/bjo.2009.177279","article-title":"Vascular endothelial growth factor inhibition in uveitis: A systematic review","volume":"95","author":"Gulati","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"R3-20261103","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12348-018-0155-6","article-title":"An update on inflammatory choroidal neovascularization: Epidemiology, multimodal imaging, and management","volume":"8","author":"Agarwal","year":"2018","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"R4-20261103","doi-asserted-by":"crossref","first-page":"101235","DOI":"10.1016\/j.preteyeres.2023.101235","article-title":"Punctate inner choroidopathy: A review of the current diagnostic and therapeutic approaches","volume":"99","author":"Kalogeropoulos","year":"2024","journal-title":"Prog Retin Eye Res"},{"key":"R5-20261103","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: A narrative review","volume":"7","author":"Anderson","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"R6-20261103","first-page":"182","article-title":"Hypoxia inducible factor-1alpha is increased in ischemic retina: Temporal and spatial correlation with VEGF expression","volume":"40","author":"Ozaki","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R7-20261103","first-page":"1030","article-title":"Retinal inflammation and reactive M\u00fcller cells: Neurotrophins\u2019 release and neuroprotective strategies","volume":"13","author":"Balzamino","year":"2024","journal-title":"Biology (Basel)"},{"key":"R8-20261103","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0002-9394(01)01103-5","article-title":"Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema","volume":"132","author":"Fine","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R9-20261103","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41420-023-01717-2","article-title":"Mechanistic insights into the alterations and regulation of the AKT signaling pathway in diabetic retinopathy","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discov"},{"key":"R10-20261103","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.3390\/biomedicines12102346","article-title":"The role of immune cells and signaling pathways in diabetic eye disease: A comprehensive review","volume":"12","author":"Barone","year":"2024","journal-title":"Biomedicines"},{"key":"R11-20261103","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-025-02249-0","article-title":"Vascular endothelial growth factor signaling in health and disease: From molecular mechanisms to therapeutic perspectives","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"R12-20261103","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/09273948.2018.1429637","article-title":"Fluorescein labeled leukocytes for in vivo imaging of retinal vascular inflammation and infiltrating leukocytes in laser-induced choroidal neovascularization model","volume":"28","author":"Agrawal","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"R13-20261103","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/09273948.2021.2002367","article-title":"Adjunctive intravitreal anti-vascular endothelial growth factor and moxifloxacin therapy in management of intraocular tubercular granulomas","volume":"31","author":"Agarwal","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"key":"R14-20261103","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2147\/DDDT.S353251","article-title":"Synergistic effect of combined sub-tenon triamcinolone and intravitreal anti-VEGF therapy for uveitic macular edema","volume":"16","author":"Lin","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"R15-20261103","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/eye.2008.388","article-title":"Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab","volume":"23","author":"Weiss","year":"2009","journal-title":"Eye (Lond)"},{"key":"R16-20261103","doi-asserted-by":"crossref","first-page":"729465","DOI":"10.1155\/2014\/729465","article-title":"The effects of intravitreal bevacizumab in infectious and noninfectious uveitic macular edema","volume":"2014","author":"Al-Dhibi","year":"2014","journal-title":"J Ophthalmol"},{"key":"R17-20261103","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/09273948.2017.1400073","article-title":"Twenty-four months follow-up of intravitreal bevacizumab injection versus intravitreal triamcinolone acetonide injection for the management of persistent non-infectious uveitic cystoid macular edema","volume":"27","author":"Lasave","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"R18-20261103","first-page":"136","article-title":"Comparison of intravitreal injection of bevacizumab and triamcinolone acetonide in the treatment of uveitic macular edema","volume":"9","author":"Rahimi","year":"2012","journal-title":"Iran J Immunol"},{"key":"R19-20261103","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2023.04.011","article-title":"Intravitreal therapy for uveitic macular edema-ranibizumab versus methotrexate versus the dexamethasone implant: The MERIT trial results","volume":"130","author":"Acharya","year":"2023","journal-title":"Ophthalmology"},{"key":"R20-20261103","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ophtha.2024.11.021","article-title":"Macular edema ranibizumab versus intravitreal anti-inflammatory therapy trial: 24-week outcomes of uveitic macular edema re-treatment","volume":"132","author":"Gonzales","year":"2025","journal-title":"Ophthalmology"},{"key":"R21-20261103","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/09273948.2024.2344709","article-title":"Treatment outcomes of intravitreal aflibercept for uveitic macular edema","volume":"33","author":"Oyeniran","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"key":"R22-20261103","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00417-013-2309-4","article-title":"Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema","volume":"251","author":"Radwan","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R23-20261103","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.ophtha.2006.11.028","article-title":"Intravitreal bevacizumab for treatment of uveitic macular edema","volume":"114","author":"Cordero Coma","year":"2007","journal-title":"Ophthalmology"},{"key":"R24-20261103","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4103\/JOCO.JOCO_128_20","article-title":"Results of intravitreal anti-vascular endothelial growth factor therapy in inflammatory choroidal neovascularization","volume":"33","author":"Zina","year":"2021","journal-title":"J Curr Ophthalmol"},{"key":"R25-20261103","doi-asserted-by":"crossref","first-page":"9982883","DOI":"10.1155\/2021\/9982883","article-title":"Inflammatory choroidal neovascular membranes: Clinical profile, treatment effectiveness, and visual prognosis","volume":"2021","author":"Carrola","year":"2021","journal-title":"J Ophthalmol"},{"key":"R26-20261103","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.ophtha.2012.05.034","article-title":"Tubercular serpiginous-like choroiditis presenting as multifocal serpiginoid choroiditis","volume":"119","author":"Bansal","year":"2012","journal-title":"Ophthalmology"},{"key":"R27-20261103","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3928\/23258160-20210727-05","article-title":"Choroidal thickness in multifocal dendritic and placoid serpiginous-like choroiditis: A comparative study","volume":"52","author":"Kawali","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R28-20261103","first-page":"118","article-title":"Inflammatory choroidal neovascular membranes in patients with noninfectious uveitis: The place of intravitreal anti-VEGF therapy","volume":"9","author":"Karti","year":"2020","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"R29-20261103","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2147\/OPTH.S34294","article-title":"Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization","volume":"6","author":"Mansour","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"R30-20261103","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.ajo.2007.02.039","article-title":"Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin","volume":"143","author":"Chan","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R31-20261103","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4103\/0301-4738.103795","article-title":"Management of recurrent inflammatory choroidal neovascular membrane secondary to Vogt-Koyanagi-Harada syndrome, using combined intravitreal injection of bevacizumab and triamcinolone acetate","volume":"60","author":"Pai","year":"2012","journal-title":"Indian J Ophthalmol"},{"key":"R32-20261103","doi-asserted-by":"crossref","first-page":"1585803","DOI":"10.1155\/2018\/1585803","article-title":"Treatment of punctate inner choroidopathy with choroidal neovascularization using corticosteroid and intravitreal ranibizumab","volume":"2018","author":"Wu","year":"2018","journal-title":"Biomed Res Int"},{"key":"R33-20261103","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4274\/tjo.09076","article-title":"Intravitreal aflibercept as an adjunct to systemic therapy in a case of choroidal neovascular membrane associated with sympathetic ophthalmia","volume":"48","author":"Saat\u00e7i","year":"2018","journal-title":"Turk J Ophthalmol"},{"key":"R34-20261103","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/IAE.0b013e318242b9da","article-title":"Intravitreal bevacizumab as primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy: Results of a 1-year prospective trial","volume":"32","author":"Zhang","year":"2012","journal-title":"Retina"},{"key":"R35-20261103","doi-asserted-by":"crossref","first-page":"440","DOI":"10.5301\/EJO.2010.6117","article-title":"Visual and optical coherence tomography outcomes of intravitreal bevacizumab and ranibizumab in inflammatory choroidal neovascularization secondary to punctate inner choroidopathy","volume":"21","author":"Cornish","year":"2011","journal-title":"Eur J Ophthalmol"},{"key":"R36-20261103","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/IAE.0b013e3182003ca8","article-title":"Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization","volume":"31","author":"Rouvas","year":"2011","journal-title":"Retina"},{"key":"R37-20261103","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2147\/TCRM.S110556","article-title":"Combined treatment in punctate inner choroidopathy","volume":"12","author":"Terelak-Borys","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"R38-20261103","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1080\/09273948.2025.2534080","article-title":"Systemic immunosuppression and secondary choroidal neovascularisation in patients with punctate inner chorioretinopathy","volume":"33","author":"Dhirachaikulpanich","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"key":"R39-20261103","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1055\/a-2467-1804","article-title":"Inflammatory choroidal neovascularization in pediatric uveitis: A case series","volume":"242","author":"Gauderon","year":"2025","journal-title":"Klin Monbl Augenheilkd"},{"key":"R40-20261103","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/bjophthalmol-2019-315257","article-title":"Twenty-four-month outcomes of inflammatory choroidal neovascularisation treated with intravitreal anti-vascular endothelial growth factors: A comparison between two treatment regimens","volume":"104","author":"Invernizzi","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R41-20261103","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10792-017-0536-0","article-title":"Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy","volume":"38","author":"Barth","year":"2018","journal-title":"Int Ophthalmol"},{"key":"R42-20261103","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/09273940802650406","article-title":"Intravitreal bevacizumab for uveitic choroidal neovascularization","volume":"17","author":"Doctor","year":"2009","journal-title":"Ocul Immunol Inflamm"},{"key":"R43-20261103","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/bjophthalmol-2013-304237","article-title":"Intravitreal bevacizumab for choroidal neovascularisation in serpiginous choroiditis","volume":"98","author":"Parodi","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R44-20261103","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1097\/IAE.0b013e3181d374dc","article-title":"Positive response to intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to punctate inner choroidopathy","volume":"30","author":"Menezo","year":"2010","journal-title":"Retina"},{"key":"R45-20261103","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00417-008-0906-4","article-title":"Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis","volume":"246","author":"Tran","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R46-20261103","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ajo.2021.07.010","article-title":"Intravitreal antivascular endothelial growth factor treatment for inflammatory choroidal neovascularization in noninfectious uveitis","volume":"236","author":"Woronkowicz","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"R47-20261103","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4103\/IJO.IJO_2968_24","article-title":"Adjunctive intravitreal anti-vascular endothelial growth factor and moxifloxacin for treating a large choroidal tuberculoma","volume":"5","author":"Patel","year":"2025","journal-title":"Indian J Ophthalmol Case Rep"},{"key":"R48-20261103","first-page":"123646","article-title":"Risk of retinal neovascularization in cases of uveitis","author":"Patel","year":"2016","journal-title":"Ophthalmology"},{"key":"R49-20261103","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3390\/ijms21041503","article-title":"Targeting neurovascular interaction in retinal disorders","volume":"21","author":"Fu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R50-20261103","doi-asserted-by":"crossref","first-page":"100742","DOI":"10.1016\/j.curtheres.2024.100742","article-title":"Immunogenicity and potential for intraocular inflammation of intravitreal anti-VEGF drugs","volume":"100","author":"Kim","year":"2024","journal-title":"Curr Ther Res Clin Exp"},{"key":"R51-20261103","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/bjo.2005.072686","article-title":"Toll-like receptors in ocular immunity and the immunopathogenesis of inflammatory eye disease","volume":"90","author":"Chang","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R52-20261103","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/jcm10030458","article-title":"Retinal vascular endothelial cell dysfunction and neuroretinal degeneration in diabetic patients","volume":"10","author":"Mrugacz","year":"2021","journal-title":"J Clin Med"},{"key":"R53-20261103","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s12035-023-03228-8","article-title":"Advanced glycation end-products (AGEs) promote endothelial cell pyroptosis under cerebral ischemia and hypoxia via HIF-1\u03b1-RAGE-NLRP3","volume":"60","author":"Han","year":"2023","journal-title":"Mol Neurobiol"},{"key":"R54-20261103","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ajo.2008.05.024","article-title":"Intravitreal bevacizumab in inflammatory ocular neovascularization","volume":"146","author":"Mansour","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R55-20261103","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/IAE.0b013e3181f2a27f","article-title":"Role of intravitreal bevacizumab in Eales disease with dense vitreous hemorrhage: A prospective randomized control study","volume":"31","author":"Patwardhan","year":"2011","journal-title":"Retina"},{"key":"R56-20261103","doi-asserted-by":"crossref","first-page":"333","DOI":"10.12669\/pjms.342.14483","article-title":"Role of intravitreal bevacizumab in management of Eale\u2019s disease","volume":"34","author":"Mehboob","year":"2018","journal-title":"Pak J Med Sci"},{"key":"R57-20261103","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1097\/QAD.0b013e3283471d97","article-title":"Bevacizumab reverts serous retinal detachment caused by tuberculosis-associated immune reconstitution inflammatory syndrome","volume":"25","author":"Ruiz-Cruz","year":"2011","journal-title":"AIDS"},{"key":"R58-20261103","doi-asserted-by":"crossref","first-page":"270","DOI":"10.5301\/ejo.5000528","article-title":"Optic nerve head tubercular granuloma successfully treated with anti-VEGF intravitreal injections in addition to systemic therapy","volume":"25","author":"Invernizzi","year":"2015","journal-title":"Eur J Ophthalmol"},{"key":"R59-20261103","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1080\/09273948.2022.2159843","article-title":"Intravitreal anti-vascular endothelial growth factor and moxifloxacin for treatment of tubercular choroidal granuloma and sub retinal abscess","volume":"32","author":"Manoharan","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"R60-20261103","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4103\/ijo.IJO_3052_21","article-title":"Refractory bilateral choroiditis due to presumed ocular tuberculosis responding to intravitreal moxifloxacin","volume":"2","author":"Babu","year":"2022","journal-title":"Indian J Ophthalmol - Case Reports"},{"key":"R61-20261103","doi-asserted-by":"crossref","first-page":"bcr2017222410","DOI":"10.1136\/bcr-2017-222410","article-title":"Intravitreal bevacizumab for postviral fever retinitis: A novel approach for early resolution of macular oedema","volume":"2018","author":"Chawla","year":"2018","journal-title":"BMJ Case Rep"},{"key":"R62-20261103","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.4103\/ijo.IJO_439_20","article-title":"Anti-vascular endothelial growth factor in the treatment of macular edema in epidemic retinitis","volume":"68","author":"Kawali","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R63-20261103","article-title":"Treatment of intermediate uveitis-associated retinal vasoproliferative tumors: A case series","author":"Elnahry","year":"2023","journal-title":"Retin Cases Brief Rep"},{"key":"R64-20261103","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000492713","article-title":"A case report of intravitreal bevacizumab for iris metastasis of small cell lung carcinoma with neovascular glaucoma","volume":"9","author":"Hidaka","year":"2018","journal-title":"Case Rep Ophthalmol"},{"key":"R65-20261103","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/IAE.0b013e3182a0e446","article-title":"Treatment of persistent serous retinal detachment in Vogt-Koyanagi-Harada syndrome with intravitreal bevacizumab during the systemic steroid treatment","volume":"34","author":"Reibaldi","year":"2014","journal-title":"Retina"},{"key":"R66-20261103","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/ceo.13453","article-title":"Effects of intravitreal bevacizumab in Gram-positive and Gram-negative models of ocular inflammation","volume":"47","author":"Lafreniere","year":"2019","journal-title":"Clin Exp Ophthalmol"},{"key":"R67-20261103","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s11095-024-03721-2","article-title":"Topical solution for retinal delivery: Bevacizumab and ranibizumab eye drops in anti-aggregation formula (AAF) in rabbits","volume":"41","author":"Giannos","year":"2024","journal-title":"Pharm Res"},{"key":"R68-20261103","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.sjopt.2015.06.002","article-title":"Posterior sub-tenon\u2019s bevacizumab injection in diabetic macular edema; A pilot study","volume":"29","author":"Falavarjani","year":"2015","journal-title":"Saudi J Ophthalmol"},{"key":"R69-20261103","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s43088-025-00598-x","article-title":"Combination therapy of intravitreal ranibizumab and sub-tenon triamcinolone for treatment of resistant diabetic macular edema: A clinical study in Egypt","volume":"14","author":"Khalil","year":"2025","journal-title":"Beni-Suef Univ J Basic Appl Sci"},{"key":"R70-20261103","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1167\/iovs.08-3148","article-title":"Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits","volume":"50","author":"Nomoto","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R71-20261103","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3341\/kjo.2013.27.4.299","article-title":"Regression of iris neovascularization after subconjunctival injection of bevacizumab","volume":"27","author":"Ryoo","year":"2013","journal-title":"Korean J Ophthalmol"},{"key":"R72-20261103","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00417-025-06738-4","article-title":"Effectiveness and cytokine profile of combined anti-vascular endothelial growth factor and corticosteroid therapy for chronic retinal vein occlusion","volume":"263","author":"Arai","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R73-20261103","first-page":"3043","article-title":"Efficiency and safety of subconjunctival injection of anti-VEGF agent-bevacizumab-in treating dry eye","volume":"9","author":"Jiang","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"R74-20261103","doi-asserted-by":"crossref","DOI":"10.1177\/24741264251358623","article-title":"Intraocular inflammation following intravitreal faricimab: Insights from five bilateral cases","author":"Dhillon","year":"2025","journal-title":"J Vitreoretin Dis"},{"key":"R75-20261103","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1080\/09273948.2025.2476061","article-title":"Increased risk of retinal vasculitis may be associated with aflibercept 8 mg: A pharmacovigilance analysis of the FAERS database","volume":"33","author":"Nowroozzadeh","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"key":"R76-20261103","doi-asserted-by":"crossref","DOI":"10.1177\/24741264251332515","article-title":"Intraocular inflammation, safety events, and outcomes after intravitreal injection of ranibizumab, aflibercept, brolucizumab, abicipar pegol, and faricimab for nAMD","author":"Stevanovic","year":"2025","journal-title":"J Vitreoretin Dis"},{"key":"R77-20261103","first-page":"24741264251330339","article-title":"Bilateral sterile granulomatous uveitis caused by intravitreal injections of faricimab","volume":"2025","author":"Hill","journal-title":"J Vitreoretin Dis"},{"key":"R78-20261103","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/IAE.0b013e3181cd47ed","article-title":"Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor","volume":"30","author":"Mezad-Koursh","year":"2010","journal-title":"Retina"},{"key":"R79-20261103","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5693\/djo.01.2016.03.001","article-title":"A cluster of presumed, noninfectious endophthalmitis after intravitreal injection of bevacizumab: Long-term follow-up","volume":"22","author":"Ricci","year":"2016","journal-title":"Digit J Ophthalmol"},{"key":"R80-20261103","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.4103\/ijo.IJO_530_18","article-title":"Commentary: The changing scenario of cluster endophthalmitis","volume":"66","author":"Kumar","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"R81-20261103","doi-asserted-by":"crossref","first-page":"694","DOI":"10.4103\/0301-4738.99855","article-title":"Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial","volume":"64","author":"Khan","year":"2016","journal-title":"Indian J Ophthalmol"},{"key":"R82-20261103","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s40123-025-01157-4","article-title":"Systemic effects of intravitreal anti-VEGF therapy: A review of safety across organ systems","volume":"14","author":"Banerjee","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"R83-20261103","doi-asserted-by":"crossref","first-page":"627674","DOI":"10.1155\/2015\/627674","article-title":"Anti-VEGF therapy and the retina: An update","volume":"2015","author":"Tah","year":"2015","journal-title":"J Ophthalmol"},{"key":"R84-20261103","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s13300-025-01791-y","article-title":"Evidence-based guidelines for intravitreal anti-VEGF therapy for diabetic retinopathy in chronic kidney disease","volume":"16","author":"Sharma","year":"2025","journal-title":"Diabetes Ther"},{"key":"R85-20261103","doi-asserted-by":"crossref","first-page":"28009","DOI":"10.1038\/s41598-025-11406-y","article-title":"Novel anti-VEGF scFv antibodies with superior in vitro and in vivo activities","volume":"15","author":"Cakan-Akdogan","year":"2025","journal-title":"Sci Rep"},{"key":"R86-20261103","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/14712598.2022.2100694","article-title":"Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: What we have learned and what should we learn further?","volume":"22","author":"Uludag","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"R87-20261103","doi-asserted-by":"crossref","first-page":"e00723","DOI":"10.1002\/prp2.723","article-title":"Biological drug therapy for ocular angiogenesis: Anti-VEGF agents and novel strategies based on nanotechnology","volume":"9","author":"Formica","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"R88-20261103","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"R89-20261103","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4103\/IJO.IJO_2973_23","article-title":"Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group","volume":"72","author":"Agarwal","year":"2024","journal-title":"Indian J Ophthalmol"},{"key":"R90-20261103","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40942-025-00719-9","article-title":"One-year results of visual response following intravitreal novel anti-VEGF injection for diabetic macular edema in a Latino population","volume":"11","author":"Salcedo-Villanueva","year":"2025","journal-title":"Int J Retina Vitreous"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2975_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:00:33Z","timestamp":1793732433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2975_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2975_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2025-11-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}